Orphenadrine Citrate (orphenadrine citrate)
Last reviewed · Source: First Databank (FDB) drug data
Overview
Orphenadrine is a centrally acting skeletal muscle relaxant.
USES: Orphenadrine is used to treat muscle spasms/pain. It is usually used along with rest, physical therapy, and other treatment.
Generic name: orphenadrine citrate
Pronunciation: (or-FEN-a-dreen)
Reference product & biosimilars
No reference, biosimilar or interchangeable associated with this drug.
Today’s intelligence on Orphenadrine Citrate
Indications
The following indications are listed for Orphenadrine Citrate:
- Muscle Spasm
Also known as: Involuntary Muscle Contraction, Muscle Spasticity, Skeletal Muscle Spasm, Spasticity.
Dosing
No dosing information is available for this tab.
Orphenadrine is administered orally or by IM or IV injection. When orphenadrine is administered IV, the drug should be given over a period of about 5 minutes with the patient in a supine position; the patient should remain in this position for 5-10 minutes after the injection. To minimize adverse reactions after parenteral administration of the drug, the patient should be assisted from the recumbent position.
No dosing information is available for this tab.
No dosing information is available for this tab.
Drug interactions
There is no enhanced messaging for this drug.
There are no contraindication interactions for this drug.
There are no severe interactions for this drug.
There are no moderate interactions for this drug.
Contraindications
There is no enhanced messaging for this drug.
There are no contraindication contraindications for this drug.
There are no severe contraindications for this drug.
There are no moderate contraindications for this drug.
Adverse reactions
There is no enhanced messaging for this drug.
There are no severe adverse reactions for this drug.
There are no less severe adverse reactions for this drug.
Precautions
No enhanced messaging available.
No enhanced messaging available.
Safe use of orphenadrine during pregnancy has not been established. The drug has caused adverse effects in animals at high doses. In one reproduction study in rats receiving 5 times the human daily dose, degenerative changes in the urinary bladder occurred in 5% of the offspring; in a subsequent study using 12 times the human daily dose, this abnormality was not observed. Orphenadrine should be used during pregnancy only when the potential benefits justify the possible risks to the fetus.
Since it is not known if orphenadrine is distributed into milk, the drug should be used with caution in nursing women.
No enhanced messaging available.
ICD codes
No ICD codes are available for this drug.
Formulary status
Search health-plan coverage for this drug by ZIP code.
Choose the first character of a health plan name.
Last reviewed · Source: First Databank (FDB) drug data
On this page
Actions
Sign in to save favorites
Saving this drug requires a free Physicians Office Resource account.